Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study von Pandit, Anuja, Bhalani, Nirav, Bhushan, B.L. Shashi, Koradia, Parshottam, Gargiya, Shweta, Bhomia, Vinay, Kansagra, Kevinkumar

Volltext

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious... von Pandit, Anuja, Bhalani, Nirav, Bhushan, B.L. Shashi, Koradia, Parshottam, Gargiya, Shweta, Bhomia, Vinay, Kansagra, Kevinkumar

Volltext

Two-year safety and efficacy of Indigenous Abluminus Sirolimus Eluting Stent. Does it differ amongst diabetics? – Data from en-ABLe- REGISTRY von Sharma, Kamal, Dani, Sameer, Desai, Devang, Kumar, Prathap, Bhalani, Nirav, Vasavada, Apurva, Trivedi, Rutvik

Volltext

TCT-627 Novel Sirolimus Eluting Stent With Fusion Coating Technology to Address the “Diabetes Issue”: 2-Year Result of the en-ABL e-Registry von Testa, Luca, Dani, Sameer, Desai, Devang, Pandya, Rashmit, Parekh, Pritesh, Vasavada, Apurva, Bhalani, Nirav, Sheth, Chirag, Shah, Dinesh

Volltext

TCT-282 Predictors of Clinical Outcomes After Implantation of Novel Sirolimus-Eluting Stent in Real-World Patient Population von Dani, Sameer, Desai, Devang, Pandya, Rashmit, Parekh, Pritesh, Vasavada, Apurva, Bhalani, Nirav, Sharma, Arvind, Sheth, Chirag, Shah, Dinesh

Volltext

TCTAP A-004 A Prospective, Multi-center Registry to Assess the Novel Sirolimus-eluting Stent with Unique Fusion Coating for Coronary Revascularization in Real World Population: The... von Dani, Sameer, Desai, Devang, Pandya, Rashmit, Vasavada, Apurva, Pillai, PrathapKumar, Bhalani, Nirav, Sharma, Arvind, Sheth, Chirag, Trivedi, Rutvik, Shah, Dinesh

Volltext

Two-year safety and efficacy of Indigenous Abluminally Sirolimus Eluting stent. Does it differ amongst diabetics? - Data from en-ABL e-REGISTRY von Sharma, Kamal, Dani, Sameer, Desai, Devang, Kumar, Prathap, Bhalani, Nirav, Vasavada, Apurva, Trivedi, Rutvik

Volltext

TCTAP A-149 Clinical Outcomes of “Real World” Patients Receiving Novel Abluminal Coated Sirolimus Eluting Stent von Dani, Sameer, Natarajapillai, Prathapkumar, Vasavada, Apurva, Thejus, Jayachandran, Parekh, Pritesh, Sharma, Kamal, Trivedi, Rutvik, Bhalani, Nirav, Sharma, Arvind, Sheth, Chirag

Volltext

TCTAP A-146 A Novel Abluminal Coated Sirolimus-eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-comers Multicenter Study von Testa, Luca, Dani, Sameer, Bhalani, Nirav, Sharma, Arvind, Sheth, Chirag, Natarajapillai, Prathapkumar, Vasavada, Apurva, Thejus, Jayachandran, Parekh, Pritesh, Sharma, Kamal, Trivedi, Rutvik

Volltext

CRT-100.83 An All-comer Ongoing en-ABL Registry With a Novel Abluminal Coated Sirolimus-eluting Stent: Two-year Clinical Outcomes in Patients With Complex Lesions von Dani, Sameer, Desai, Devang, Pandya, Rashmit, Vasavada, Apurva, Pillai, Prathap Kumar N., Bhalani, Nirav, Sharma, Arvind, Sheth, Chirag, Trivedi, Rutvik, Singh, Jitendra, Shah, Dinesh

Volltext

A PROCESS FOR THE PREPARATION OF EDOXABAN AND ITS INTERMEDIATES von PATEL, Kalpesh Ravajibhai, THAKRAR, Virendra Haridas, BHALANI, Shyam Kishorbhai, SUNDARANI, Kripalsingh Ajitsingh, MEHTA, Tushar Bharatkumar, PRAJAPATI, Nitin Vasantbhai, SUTARIYA, Nirav Bavanjibhai

Volltext bestellen